• NMPA approves Rigen-Bio’s disposable thyroid biopsy needle for marketing in China
  • 2022-06-13
  • Recently, Shanghai Municipal Drug Administration approves Rigen-Bio’s disposable thyroid biopsy needle, which was independently developed and designed for marketing in China. [Registration Certificate No. 20212140622] And filed with the State Drug Administration (NMPA). 

    The needle specifically designed for thyroid biopsy is the only product in China to obtain thyroid tissue samples through percutaneous puncture with many advantages , such as easy to operate, and sampling accurately. There are 7 different specifications, 26G, 25G, 24G, 23G, 22G, 21G, 20G for clinical choices.

    细针 内容图2 新600.png

  • Dream building - 2020 Rigen Biotech annual meeting
  • 2020-01-20
  • Time flies, time changes.In a flash, the busy year of 2019 has passed.With passion and challenges, a brand new 2020 has arrived. On the occasion of farewell to the old and welcome to the new,the Shanghai Rigen Biotech  Annual Meeting will be held on the afternoon of January 10, 2020 at the Bili Palace Hotel.

    Mr. Hong Gendong, Chairman of Shanghai Rigen Biotech , Ms. Bao Wenjing, General Manager, company executives and employees of the company gathered together to share the gains and joys of the past year and look forward to a bright future together.

    The annual meeting consists of three parts: leaders' speech, excellent commendation and dinner party.

    The chairman and general manager gave speeches respectively, affirmed the performance of Shanghai Rigen Biotech in 2019, and clarified the company's overall plan and goals for 2020:

    The company's success is inseparable from the joint efforts of every Rigen Bio-Human. This commendation has a special award for best sales performance, best sales management, best sales support, excellent employees and excellent team, which will recognize the employees with outstanding performance in 2019.

    The staff of each department presented carefully prepared programs, the opening street dance of the explosion, showing off the whole audience;  Then there were small dramas-dating conferences, series of songs and stand-up crosstalk, which fully demonstrated our talents as Rigen Bio-human.  Finally, the first show brought by Rui Jing Biology Chorus: "Tomorrow will be better".The whole party was brilliant and won applause from the audience. The lottery draw was delighted with music, and the selection of third prize, second prize, first prize, and special prize set off a wave of climax at the annual meeting.

    The dinner not only brought cheers and laughter to everyone, but also brought colleagues' hearts closer together. The leaders of the company interacted with the employees affectionately, and the climax of the whole meeting was repeated, showing the joy and harmony of the big family of Rigen Biotech .

    In the past year, we have smiled, had a hard time, and have also learned. In the face of 2020, we are full of longing, step by step, and solidly write a brighter future.

  • Shanghai Rigen Biotechnology Co., Ltd. was approved as a high-tech enterprise
  • 2019-12-30
  • Shanghai Rigen Biotechnology Co., Ltd. was officially recognized as a national high-tech enterprise in December 2019 and became a national high-tech enterprise, enjoying all the preferential policies.

  • The inauguration meeting of the Professional Committee of the Oncology Branch of the Chinese Medical
  • 2019-06-29
  • On June 28, 2019, during the Chinese Oncology Conference, the Professional Committee of the Oncology Branch of the Chinese Medical Association was established and held academic activities. At the same time, the "multi-center clinical trial" project carried out by Tianjin Medical University Cancer  Institute & Hospital and many domestic hospitals was successfully held during this meeting. Professor Zheng Xiangqian from Tianjin Medical University Cancer  Institute & Hospital , Professor Guan Haixia from the First Hospital of China Medical University, Professor Liu Zhiyan from the Department of Pathology, Qilu Hospital of Shandong University, and Professor Shao Jianyong from the Sun Yat-sen University Cancer center jointly discuss the progress and propose new ideas.

    Shanghai Ruijing Biotechnology Co., Ltd. is committed to individualized medical treatment of tumors and participated in the multi-center clinical project research throughout.

    The academic feast was held, which attracted many media's follow-up reports.